Pelvic lymph node metastases from bladder and prostate cancer magnetic resonance imaging with ultrasmall superparamagnetic iron oxyde sinerem.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-004567-29-IT

Enrollment

Registered

2007-02-14

Start date

2004-11-22

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SUSPECT LYMPHONODAL METASTASES MedDRA version: 6.1 Level: PT Classification code 10036909

Interventions

Product Name: SINEREM Product Code: G 534-70 Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: Iron oxide, nanoparticles Concentration unit: mg milligram(s) Concen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026